416 related articles for article (PubMed ID: 25927139)
1. Inhibition of Plk1 represses androgen signaling pathway in castration-resistant prostate cancer.
Zhang Z; Chen L; Wang H; Ahmad N; Liu X
Cell Cycle; 2015; 14(13):2142-8. PubMed ID: 25927139
[TBL] [Abstract][Full Text] [Related]
2. Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer.
Zhang Z; Hou X; Shao C; Li J; Cheng JX; Kuang S; Ahmad N; Ratliff T; Liu X
Cancer Res; 2014 Nov; 74(22):6635-47. PubMed ID: 25252916
[TBL] [Abstract][Full Text] [Related]
3. Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer.
Hou X; Li Z; Huang W; Li J; Staiger C; Kuang S; Ratliff T; Liu X
Prostate; 2013 Sep; 73(12):1352-63. PubMed ID: 23661607
[TBL] [Abstract][Full Text] [Related]
4. Cotargeting Polo-Like Kinase 1 and the Wnt/β-Catenin Signaling Pathway in Castration-Resistant Prostate Cancer.
Li J; Karki A; Hodges KB; Ahmad N; Zoubeidi A; Strebhardt K; Ratliff TL; Konieczny SF; Liu X
Mol Cell Biol; 2015 Dec; 35(24):4185-98. PubMed ID: 26438599
[TBL] [Abstract][Full Text] [Related]
5. Drugging Plk1: An attractive approach to inhibit androgen receptor signaling.
Strebhardt K
Cell Cycle; 2015; 14(14):2193-4. PubMed ID: 26030710
[No Abstract] [Full Text] [Related]
6. Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer.
Mao F; Li J; Luo Q; Wang R; Kong Y; Carlock C; Liu Z; Elzey BD; Liu X
Mol Cancer Ther; 2018 Jul; 17(7):1554-1565. PubMed ID: 29716963
[TBL] [Abstract][Full Text] [Related]
7. Plk1 is upregulated in androgen-insensitive prostate cancer cells and its inhibition leads to necroptosis.
Deeraksa A; Pan J; Sha Y; Liu XD; Eissa NT; Lin SH; Yu-Lee LY
Oncogene; 2013 Jun; 32(24):2973-83. PubMed ID: 22890325
[TBL] [Abstract][Full Text] [Related]
8. Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer.
Li J; Wang R; Kong Y; Broman MM; Carlock C; Chen L; Li Z; Farah E; Ratliff TL; Liu X
Mol Cancer Ther; 2017 Mar; 16(3):469-479. PubMed ID: 28069876
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer.
Shao C; Ahmad N; Hodges K; Kuang S; Ratliff T; Liu X
J Biol Chem; 2015 Jan; 290(4):2024-33. PubMed ID: 25505174
[TBL] [Abstract][Full Text] [Related]
10. Combining p53 stabilizers with metformin induces synergistic apoptosis through regulation of energy metabolism in castration-resistant prostate cancer.
Chen L; Ahmad N; Liu X
Cell Cycle; 2016; 15(6):840-9. PubMed ID: 26900800
[TBL] [Abstract][Full Text] [Related]
11. Novel Dual BET and PLK1 Inhibitor WNY0824 Exerts Potent Antitumor Effects in CRPC by Inhibiting Transcription Factor Function and Inducing Mitotic Abnormality.
Xu Y; Wang Q; Xiao K; Liu Z; Zhao L; Song X; Hu X; Feng Z; Gao T; Zuo W; Zeng J; Wang N; Yu L
Mol Cancer Ther; 2020 Jun; 19(6):1221-1231. PubMed ID: 32220972
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL
Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927
[TBL] [Abstract][Full Text] [Related]
13. Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer.
Solanes-Casado S; Cebrián A; Rodríguez-Remírez M; Mahíllo I; García-García L; Río-Vilariño A; Baños N; de Cárcer G; Monfort-Vengut A; Castellano V; Fernández-Aceñero MJ; García-Foncillas J; Del Puerto-Nevado L
Biomed Pharmacother; 2021 Dec; 144():112347. PubMed ID: 34700228
[TBL] [Abstract][Full Text] [Related]
14. Cotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer.
Chen L; Li J; Farah E; Sarkar S; Ahmad N; Gupta S; Larner J; Liu X
Mol Cancer Ther; 2016 Sep; 15(9):2107-18. PubMed ID: 27390342
[TBL] [Abstract][Full Text] [Related]
15. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
[No Abstract] [Full Text] [Related]
16. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
Thomas C; Lamoureux F; Crafter C; Davies BR; Beraldi E; Fazli L; Kim S; Thaper D; Gleave ME; Zoubeidi A
Mol Cancer Ther; 2013 Nov; 12(11):2342-55. PubMed ID: 23966621
[TBL] [Abstract][Full Text] [Related]
17. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
[TBL] [Abstract][Full Text] [Related]
18. Essential Role of Polo-like Kinase 1 (Plk1) Oncogene in Tumor Growth and Metastasis of Tamoxifen-Resistant Breast Cancer.
Jeong SB; Im JH; Yoon JH; Bui QT; Lim SC; Song JM; Shim Y; Yun J; Hong J; Kang KW
Mol Cancer Ther; 2018 Apr; 17(4):825-837. PubMed ID: 29437878
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
20. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
